SCHEDULE: Jorey Chernett Discloses 10.85% Stake in Neuronetics

Jorey Chernett has reported a beneficial ownership of 10.85% of Neuronetics, Inc.'s common stock as of March 17, 2026.

Summary

• Jorey Chernett, a U.S. citizen, reported beneficial ownership of 7,516,404 shares of Neuronetics, Inc. common stock.
• This represents 10.85% of the outstanding shares of Neuronetics, Inc.
• The percentage is based on 69,276,593 shares outstanding as of March 10, 2026, as disclosed in the Issuer's Registration Statement on Form S-3.
• Chernett holds sole voting power and sole dispositive power over all 7,516,404 shares.
• The securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a substantial individual stake of over 10% by Jorey Chernett suggests confidence in Neuronetics, Inc., even if the stated intent is passive.

Positives

• Jorey Chernett's beneficial ownership of 10.85% of Neuronetics, Inc. common stock indicates a significant individual investment, which can be interpreted as a vote of confidence in the company's value or future prospects.
• The statement that the securities were not acquired for the purpose of changing or influencing control (other than Rule 14a-11 nominations) suggests a potentially passive, long-term investment stance.

Negatives

• The filing itself does not contain any information that would be considered negative regarding Neuronetics, Inc.'s operational or financial performance.

Risks

• The filing does not disclose specific business or financial risks for Neuronetics, Inc. It is a regulatory disclosure of ownership.

Industry Context

StockSavvy.ai notes that significant individual ownership disclosures, such as this Schedule 13G, can sometimes precede increased investor scrutiny or potential activist interest, even when the filing states a passive intent. For companies in the medical device or neuro-technology sector like Neuronetics, a substantial stake by an individual investor might be interpreted as a vote of confidence in the company's technology or market position, especially if the investor has a track record in the industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant individual shareholder could be viewed positively, potentially increasing investor confidence and market liquidity.
• Management: Management may need to be aware of a large shareholder's presence, even if the stated intent is passive, as their interests could align or diverge on strategic matters.

Key Dates

Keywords

Neuronetics, Jorey Chernett, Beneficial Ownership, NNI, Common Stock, SEC Filing, Schedule 13G, Investment, Shareholder